Ann: Encouraging data from 2nd dose cohort in CLTX CAR T trial, page-20

It really is and It’s only a matter of time and patience. Agree mate, there’s more than enough info in past treads especially from yourself.

I’m in the red too, opportunity cost not worrying me in the slightest here. The upside once we see some more efficacy will far outweigh any lost opportunity. All the indicators are there now for our lead candidate CHM 1101 to de-risk any investment in CHM. All set to continue to buy lower if need be after talking to the right people and doing more DD. Plus a certain Oil play MAY have provided more profits for me today to continue the buying lower, it's all going here. We have seen this scenario in biotech's turn on a dime before for a lot of upside very quickly especially when the broker price suppression stops. Would be very interesting to see the broker data if anyone can get it.

Something you have made clear and needs to be reiterated is disease control/stability in GBM the most aggressive form of brain cancer is a huge result at these low doses and is vastly under rewarded and misunderstood by the market thus far. You notice in the presentation by Jenn (didn’t know she was Canadian - I like her even more now) on the Finance News Network interview on YouTube posted by @Specyray on the media thread. Jenn explains the results today are very topline as they are continuing to see a strong safety signal. Alot of data is still under assessment.

Cohort 1 saw local progression of disease after week 8. The longer we go without results now the longer no disease progression and more chance of PR or CR hence why still under assessment. Which as discussed are all very much a bonus in trial designed for safety. Jenn concluded by saying very exciting to see that positive safety and the emerging efficacy in the second dose cohort. What an outcome for patients I wish them all the best!

I like how understated Jenn is using words like encouraging and positive rather than shouting salesperson jargon from the rooftops.